- [ADVANCED HEALTHCARE MATERIALS] Oligonucleotide-Linked Lipid Nanoparticles as a VersatilemRNA Nanovaccine Platform
- 관리자 |
- 2025-01-06 11:00:07|
- 17
- 2025-01-06 11:00:07|
[Title]
Oligonucleotide-Linked Lipid Nanoparticles as a VersatilemRNA Nanovaccine Platform
[Author]
San Hae Im, Youseung Chung, Nevena Duskunovic, Heewon Choi, Su-Hyung Park,*and Hyun Jung Chung*
S. H. Im, N. Duskunovic, H. Choi, H. J. Chung
Department of Biological Sciences Korea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea
Y. Chung, S.-H. Park
Graduate School of Medical Science and Engineering Korea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea
S.-H. Park
TheCenter for Epidemic Preparedness Korea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea
* corresponding author
[Abstract]
An effective delivery platform is crucial for the development of mRNAvaccines and therapeutics. Here, a versatile platform utilizingcholesterol-modified oligonucleotides (L-oligo) that bind to the mRNA withinlipid nanoparticles (LNP), and enables the effective delivery of the mRNA intotarget cells is introduced. mRNA incorporated into LNPs via linkage withL-oligo, termed oligonucleotide-linked LNP (lnLNP), is superior in cellularuptake and transfection efficiency in target cells in vitro and in vivo, comparedto the conventional LNP formulations. It is further applied lnLNP as an mRNAvaccine platform for SARS-CoV-2, demonstrating robust induction ofneutralizing activity as well as polyfunctional SARS-CoV-2-specific T-cellresponse in vivo. The current strategy can be versatilely applied to differentLNP platforms, for vaccine and therapeutic applications against variousdiseases, such as infections and cancers.
Oligonucleotide-Linked Lipid Nanoparticles as a VersatilemRNA Nanovaccine Platform
[Author]
San Hae Im, Youseung Chung, Nevena Duskunovic, Heewon Choi, Su-Hyung Park,*and Hyun Jung Chung*
S. H. Im, N. Duskunovic, H. Choi, H. J. Chung
Department of Biological Sciences Korea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea
Y. Chung, S.-H. Park
Graduate School of Medical Science and Engineering Korea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea
S.-H. Park
TheCenter for Epidemic Preparedness Korea Advanced Institute of Science and Technology Daejeon 34141, Republic of Korea
* corresponding author
[Journal]
Adv. Healthcare Mater. 2024, 13, 2401868[Abstract]
An effective delivery platform is crucial for the development of mRNAvaccines and therapeutics. Here, a versatile platform utilizingcholesterol-modified oligonucleotides (L-oligo) that bind to the mRNA withinlipid nanoparticles (LNP), and enables the effective delivery of the mRNA intotarget cells is introduced. mRNA incorporated into LNPs via linkage withL-oligo, termed oligonucleotide-linked LNP (lnLNP), is superior in cellularuptake and transfection efficiency in target cells in vitro and in vivo, comparedto the conventional LNP formulations. It is further applied lnLNP as an mRNAvaccine platform for SARS-CoV-2, demonstrating robust induction ofneutralizing activity as well as polyfunctional SARS-CoV-2-specific T-cellresponse in vivo. The current strategy can be versatilely applied to differentLNP platforms, for vaccine and therapeutic applications against variousdiseases, such as infections and cancers.